A woman who lost over two stone in just four months has revealed how she was able to quit weight-loss jabs for good by 'micro ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

By Christy Santhosh (Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United ...

Novo Nordisk saw sales growth for its diabetes and obesity care segment slow in the first half of 2025, confirming investor ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat distribution, with greater weight loss linked to better outcomes, a study ...

As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company ...